GlassScriptPhysician profile
Sasha Gunther
NPI 1336865468
$5,472.29
in general payments reported to CMS, 2019-2025
48 companies · $3,015 in 2025
The $3,015 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,457 · 2025: $3,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,844 · Education: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.37 |
| Education | $627.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $351.65 | 2024-2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $351.37 | 2024-2025 | Imfinzi, Lynparza, Enhertu |
| Abbvie INC. | $332.34 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $330.32 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $243.22 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $242.82 | 2024-2025 | Reblozyl |
| Genzyme Corporation | $229.72 | 2024-2025 | |
| Daiichi Sankyo INC. | $222.93 | 2024-2025 | Enhertu, Datroway |
| Incyte Corporation | $185.95 | 2024-2025 | Jakafi |
| Lilly USA, LLC | $184.65 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $177.58 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.43 | 2024-2025 | |
| Beone Medicines USA, INC. | $175.87 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $161.03 | 2024 | |
| Gilead Sciences, INC. | $151.14 | 2025 | Trodelvy |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $149.68 | 2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $133.22 | 2024-2025 | Fruzaqla, Iclusig |
| Stemline Therapeutics INC. | $125.00 | 2025 | Orserdu |
| Asd Specialty Healthcare, LLC | $122.85 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $109.96 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $100.27 | 2024-2025 | Tecentriq, Polivy, Phesgo |
| Seagen INC. | $92.99 | 2025 | |
| Eisai INC. | $87.70 | 2024-2025 | |
| Celgene Corporation | $83.49 | 2024-2025 | Reblozyl |
| Janssen Biotech, INC. | $75.95 | 2024 | Balversa, Akeega, Erleada |
| Puma Biotechnology, INC. | $69.00 | 2024-2025 | |
| Sobi, INC | $58.78 | 2024-2025 | |
| Tersera Therapeutics LLC | $56.85 | 2025 | Quzyttir |
| Caris Mpi, INC. | $56.59 | 2025 | Mi Cancer Seek |
| Geron Corporation | $50.58 | 2025 | Rytelo |
| Sumitomo Pharma America, INC. | $48.85 | 2024-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $46.94 | 2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Array Biopharma INC | $41.84 | 2025 | Mektovi, Braftovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $41.54 | 2024-2025 | |
| Emd Serono, INC. | $41.35 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $36.83 | 2025 | Xpovio |
| Amneal Pharmaceuticals LLC | $35.71 | 2024 | Avastin |
| Glaxosmithkline, LLC. | $34.73 | 2024 | Ojjaara |
| Genmab U.S., INC. | $29.46 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $27.77 | 2025 | Besremi |
| Springworks Therapeutics, INC. | $25.47 | 2025 | |
| Recordati_rare_diseases_inc. | $25.08 | 2025 | Enjaymo |
| Azurity Pharmaceuticals, INC. | $23.17 | 2025 | Danziten |
| Tolmar, INC. | $21.40 | 2024 | |
| Pharmacosmos Therapeutics INC. | $20.45 | 2025 | Monoferric |
| Accord Healthcare, INC. | $19.81 | 2024 | |
| Servier Pharmaceuticals LLC | $18.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Gunther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.